Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acetylon Pharma gets two therapeutic discovery project grants
The grants were awarded by the Internal Revenue Service and National Institutes of Health to reimburse a portion of research and development investment by Acetylon in two of
The grants were awarded by the Internal Revenue Service and National Institutes of Health to reimburse a portion of research and development investment by Acetylon in two of
Lannett posted a net loss of $403.561 for the first quarter 2010, or $0.02 loss per diluted share, compared to net loss of $2.86m, or $0.11 per diluted
Catalent said that this expansion will enable the company to offer formulation development and optimisation services in its Winchester, Kentucky facility and complements that site’s existing pilot scale
The $244,479 grant includes the development of vaccines to prevent infections by Yersinia, Salmonella and Staphylococcus bacteria. The QTDP program, included as part of the Patient Protection and
ASA404 is a tumor-vascular disrupting agent (tumor-VDA). Novartis signed an exclusive licensing agreement with Antisoma for the worldwide rights to ASA404 in April 2007. In March 2010, ASA404
Sage Bionetworks said that a team of network biologists, systems biologists, statistical geneticists and computational biologists use coherent datasets containing clinical, genetic and molecular layers of information to
AOBO is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialisation of prescription and OTC products. AOBO chairman and CEO Tony Liu said that
Lotus Pharma has posted a net income of $6.7m for the third quarter 2010, or $0.12 per diluted share, compared to net income of $5.39m, or $0.11 per
HES is derived from waxy maize starch and can be metabolised by the body’s enzymes. Fresenius Kabi provided Boehringer with its HESylation Technology to manufacture HES conjugated to
Centocor Ortho Biotech said that the sBLA includes inhibition of the progression of structural damage and maintenance of improvement in signs and symptoms and physical function in the